The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
hopefully they are busy making sure whatever needs to be done to make the half years numbers is being done
doesnt make sense to revoke the licence when the deal is so far down the road. Why would the EG want to start all over again? that could take years to put a new syndicate together. Most of the issues causing previous delays have only been able to be solved by the government (eg security/permits etc) and totally outside Kefis control and a new syndicate would require the same comfort on security etc as currently required. Probably just some official trying to look like a big man but unlikely to happen in my view
Agreed - I was just including the last month but back to March its around £45m if you take the 2 without values at £5m each
Thats £30m of contracts announced in the last month alone. Fantastic
and order book grew by 39% in just 5 months!
won almost as much in orders in 5 months as turnover in the whole of last year!
I think it was "50% every six months".......
Mo buying a decent amount might help (or Cathal buying more - if he thought they were a buy at 26.5p they are half that now)
Thanks Slimbo. Good to see someone prepared to do some anlysis for a change rather than just throw their toys about.
I pretty much came to the same conclusions for my analysis (£8m EBITDA on £50m etc)
I got the clear impression that Mo is definitely not going to overpromise which in the short term may disappoint some (spin outs etc) but i think his manner will be more appealing to II's than Cathal. And we dont need many to start to see the share price move upwards.
On the cash front - when youre a small co dealing with much bigger guys it gives them a lot of comfort to see you have a buffer and arent living on the edge so it makes perfect sense to me to retain that around £15m.
Indeed - we had contract announcements 25/3 4/5 5/5 18/5 1/6 what do people want??!!!
as warren buffet says successful investing is a transfer of wealth from the impatient to the patient
While the reported numbers for 2021 are as expected, to grow the order book by 40% in 5 months is pretty impressive and bodes well for the future.
I'd rather they made money!
On tuesday we should have a better handle on EBITDA (and cash position) to enable an indicative valuation
The recent tech rout in the US has shown that revenue multiples are useless. If it isnt profitable revenue its worth nothing
" It is expected that Shareholders entitled to receive payments in respect of the proceeds of the redemption of the B Shares will receive payment by 31 May "
so folks shouldnt expect it to pop in their cash accounts on the 19th just for clarity